Evaluation of safety of induced pluripotent stem cells by genome integrity

DOI 52 References
  • Watanabe Akira
    Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan The Institute for Integrated Cell-Material Sciences, Kyoto University, Kyoto, Japan
  • Amano Naoki
    Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan
  • Tokunaga Yumieu
    Amelieff Co. Ltd., Kobe, Japan
  • Poolsap Unyanee
    Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan
  • Yamanaka Shinya
    Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan The Institute for Integrated Cell-Material Sciences, Kyoto University, Kyoto, Japan

Search this article

Abstract

The discovery of induced pluripotent stem (iPS) cells have opened the doors for further disease research, drug screening, as well as regenerative medicine. To achieve clinical application of iPS cells, it is important to select proper iPS cell lines that do not harbor the risk of tumorigenicity. Thus, it is desired to establish methodologies for evaluating the safety of iPS cells, particularly in terms of genome integrity. Massively parallel sequencing can be used to monitor genomic aberrations such as the subchromosomal and the single nucleotide variations. Refined mutation analyses of iPS and founder cells revealed that some of the iPS cell-specific variations were also detected in rare populations of the founder cells by consequence of capturing the heterogeneity of the founder cells. In this review, we highlight recent analyses used to evaluate the genome integrity of iPS cells, discuss future of directions for precise assessment of the safety of iPS cells, and address issues that should be overcome.

Journal

References(52)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top